2023 Q1 Form 10-K Financial Statement

#000166357723000137 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $5.000K $5.000K $279.3K
YoY Change -91.66% -98.02% -57.9%
Cost Of Revenue $0.00 $4.808K
YoY Change 45.7%
Gross Profit $5.000K $5.000K $274.5K
YoY Change -91.45% -98.02% -58.42%
Gross Profit Margin 100.0% 100.0% 98.28%
Selling, General & Admin $128.3K $118.0K $494.2K
YoY Change -3.87% 17.25% 8.82%
% of Gross Profit 2565.2% 2359.6% 180.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.640K $4.740K $18.74K
YoY Change 1.09% 0.85% 4.46%
% of Gross Profit 92.8% 94.8% 6.83%
Operating Expenses $132.9K $122.7K $512.9K
YoY Change -3.7% 16.53% 8.66%
Operating Profit -$127.9K -$117.7K -$238.4K
YoY Change 60.8% -179.78% -226.77%
Interest Expense $1.384M -$282.9K $1.163M
YoY Change -611.04% -11.55% -184.85%
% of Operating Profit
Other Income/Expense, Net $1.387M $986.5K
YoY Change 927.67% -21.76%
Pretax Income -$1.515M -$400.6K -$1.225M
YoY Change 606.26% 142.22% 14.18%
Income Tax
% Of Pretax Income
Net Earnings -$1.515M -$400.6K -$1.225M
YoY Change 606.26% 142.22% 14.18%
Net Earnings / Revenue -30301.12% -8011.6% -438.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.33 -$0.09 -$0.27
COMMON SHARES
Basic Shares Outstanding 4.594M shares 4.540M shares 4.540M shares
Diluted Shares Outstanding 4.540M shares 4.540M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.14K $81.38K $81.38K
YoY Change 16.1% 23.23% 23.23%
Cash & Equivalents $29.14K $81.38K
Short-Term Investments
Other Short-Term Assets $3.810K $9.500K $9.500K
YoY Change -23.8% 16.85% 16.85%
Inventory
Prepaid Expenses
Receivables $40.18K $19.07K $19.07K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $73.13K $109.9K $110.0K
YoY Change 108.17% 48.09% 48.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $132.7K $136.8K $136.8K
YoY Change -10.6% -10.59% -10.6%
TOTAL ASSETS
Total Short-Term Assets $73.13K $109.9K $110.0K
Total Long-Term Assets $132.7K $136.8K $136.8K
Total Assets $205.9K $246.8K $246.8K
YoY Change 12.13% 8.58% 8.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $126.1K $1.202M $1.202M
YoY Change -86.66%
Accrued Expenses $2.110M $1.956M $1.956M
YoY Change 32.32% 32.59% 32.59%
Deferred Revenue
YoY Change
Short-Term Debt $433.6K $433.6K $433.6K
YoY Change -5.92% -5.92% -5.92%
Long-Term Debt Due $40.00K $40.00K $40.00K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $2.726M $3.645M $3.645M
YoY Change -11.11% 19.07% 19.07%
LONG-TERM LIABILITIES
Long-Term Debt $5.635M $3.242M $3.242M
YoY Change 105.16% 25.59% 25.59%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $5.635M $3.242M $3.242M
YoY Change 105.16% 25.59% 25.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.726M $3.645M $3.645M
Total Long-Term Liabilities $5.635M $3.242M $3.242M
Total Liabilities $8.362M $6.887M $6.887M
YoY Change 43.82% 22.05% 22.05%
SHAREHOLDERS EQUITY
Retained Earnings -$38.51M -$37.00M
YoY Change 3.42%
Common Stock $4.540K $4.540K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.156M -$6.641M -$6.641M
YoY Change
Total Liabilities & Shareholders Equity $205.9K $246.8K $246.8K
YoY Change 12.13% 8.58% 8.57%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$1.515M -$400.6K -$1.225M
YoY Change 606.26% 142.22% 14.18%
Depreciation, Depletion And Amortization $4.640K $4.740K $18.74K
YoY Change 1.09% 0.85% 4.46%
Cash From Operating Activities -$51.72K -$45.51K $45.17K
YoY Change 26.32% -129.59% -87.94%
INVESTING ACTIVITIES
Capital Expenditures $530.00 $520.00 $2.530K
YoY Change -112.13%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$525.00 -$520.00 -$2.530K
YoY Change -87.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -$27.30K
YoY Change -100.0% -91.56%
NET CHANGE
Cash From Operating Activities -$51.72K -45.51K $45.17K
Cash From Investing Activities -$525.00 -520.0 -$2.530K
Cash From Financing Activities 0.000 -$27.30K
Net Change In Cash -$52.24K -46.03K $15.34K
YoY Change -373.66% -49.12%
FREE CASH FLOW
Cash From Operating Activities -$51.72K -$45.51K $45.17K
Capital Expenditures $530.00 $520.00 $2.530K
Free Cash Flow -$52.25K -$46.03K $42.64K
YoY Change 27.61% -129.92% -89.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001085277
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
usd
CY2022 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
CY2022 us-gaap Payments For Loans
PaymentsForLoans
usd
CY2022 us-gaap Interest Paid
InterestPaid
usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
usd
CY2021 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
usd
CY2022 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
usd
CY2021 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
usd
CY2022 SKVI Common Stock Payable Conversion Of Debt Value
CommonStockPayableConversionOfDebtValue
usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
usd
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
shares
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-25911
CY2022 dei Entity Registrant Name
EntityRegistrantName
Skinvisible, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0344219
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
6320 South Sandhill Road
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 10
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89120
CY2022 dei City Area Code
CityAreaCode
702
CY2022 dei Local Phone Number
LocalPhoneNumber
433.7154
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
551261 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4593843 shares
CY2022 dei Auditor Name
AuditorName
Gries & Associates, LLC
CY2022 dei Auditor Location
AuditorLocation
Denver, Colorado
CY2022 dei Auditor Firm
AuditorFirmId
6778
CY2022Q4 us-gaap Cash
Cash
81378 usd
CY2021Q4 us-gaap Cash
Cash
66037 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
19073 usd
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
82 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9495 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8125 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
109946 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
74244 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
136847 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
153055 usd
CY2022Q4 us-gaap Assets
Assets
246793 usd
CY2021Q4 us-gaap Assets
Assets
227299 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1201937 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1039661 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1955820 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1475067 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
27299 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
433600 usd
CY2021Q4 us-gaap Loans Payable
LoansPayable
433600 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
40000 usd
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
40000 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
13629 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
45664 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3644986 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3061293 usd
CY2022Q4 SKVI Debt Instrument Related Party Unamortized Discount Premium Net
DebtInstrumentRelatedPartyUnamortizedDiscountPremiumNet
1228066 usd
CY2021Q4 SKVI Debt Instrument Related Party Unamortized Discount Premium Net
DebtInstrumentRelatedPartyUnamortizedDiscountPremiumNet
1837918 usd
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2992143 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2382291 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
101808 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
152642 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
250267 usd
CY2021Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
199433 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6887396 usd
CY2021Q4 us-gaap Liabilities
Liabilities
5643017 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4539843 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4539843 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4539843 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4539843 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4540 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4540 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30352905 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30352905 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36998048 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35773161 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6640603 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5415716 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
246793 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
227299 usd
CY2022 us-gaap Revenues
Revenues
279296 usd
CY2021 us-gaap Revenues
Revenues
663426 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
4808 usd
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
3300 usd
CY2022 us-gaap Gross Profit
GrossProfit
274488 usd
CY2021 us-gaap Gross Profit
GrossProfit
660126 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18738 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17939 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
494182 usd
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
454107 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
512920 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
472046 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-238432 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
188080 usd
CY2022 us-gaap Interest Expense
InterestExpense
1162869 usd
CY2021 us-gaap Interest Expense
InterestExpense
1213043 usd
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
32035 usd
CY2021 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-157478 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
144379 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
109688 usd
CY2022 us-gaap Other Expenses
OtherExpenses
986455 usd
CY2021 us-gaap Other Expenses
OtherExpenses
1260833 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-1224887 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-1072753 usd
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.27
CY2021 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.24
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4539843 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4539843 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4539843 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4539843 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4454779 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
111816 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-1072753 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5415716 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-1224887 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6640603 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-1224887 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-1072753 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
18738 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17939 usd
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
660686 usd
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
645686 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
144379 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
109688 usd
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
32035 usd
CY2021 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-157478 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1370 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1625 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-18991 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7636 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
306655 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
174166 usd
CY2021 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-7616 usd
CY2022 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
480753 usd
CY2021 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
563382 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
45170 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
374605 usd
CY2022 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
2530 usd
CY2021 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
20864 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2530 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20864 usd
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
27299 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
25200 usd
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
180000 usd
CY2021 us-gaap Payments For Loans
PaymentsForLoans
118400 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-27299 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-323600 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15341 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30141 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66037 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35896 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81378 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66037 usd
CY2021 us-gaap Interest Paid
InterestPaid
12631 usd
CY2021 SKVI Common Stock Payable Conversion Of Debt Value
CommonStockPayableConversionOfDebtValue
59602 usd
CY2022Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
136847 usd
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-03-06
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-1224887 usd
us-gaap Net Income Loss
NetIncomeLoss
-36998048 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zpcWx8LDM8ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Use of estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"/>The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"> </p>
CY2022Q4 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
4572284 usd
CY2022 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
23609820 shares
CY2022 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
27299 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
25200 usd
CY2022Q4 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
0 usd
CY2021Q4 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
27299 usd
CY2019Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2464480 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
966203 usd
CY2019Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
617915 usd
CY2019Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
64423 usd
CY2019Q2 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Reported Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseReportedClaimsAmount
11942 usd
CY2019Q2 us-gaap Advance Royalties
AdvanceRoyalties
110245 usd
us-gaap Debt Instrument Description
DebtInstrumentDescription
The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
148273 usd
CY2021Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
153591 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
129535 usd
CY2019Q4 us-gaap Taxes And Licenses
TaxesAndLicenses
1000000 usd
CY2022 SKVI Percent Payment Due To Avoid Termination
PercentPaymentDueToAvoidTermination
0.50 pure
CY2022 SKVI License Fee Agreement Terms
LicenseFeeAgreementTerms
As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USO $1,000,000) (''License Fee'').
SKVI License Revenues
LicenseRevenues
1000000 usd
CY2022 SKVI License Revenues2
LicenseRevenues2
250000 usd
CY2020Q2 us-gaap Payments To Acquire Management Contract Rights
PaymentsToAcquireManagementContractRights
100000 usd
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21 pure
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
37000000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
37000000.0 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
15700000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7800000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3300000 usd
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
7800000 usd
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
3300000 usd
CY2022Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
37000000 usd
CY2021Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
15700000 usd
CY2022 SKVI Schedule Of Option Summary
ScheduleOfOptionSummary
<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfOptionSummary_zITZSFtYbGp3" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - 10. STOCK OPTIONS AND WARRANTS - Schedule of Option Summary (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231_zMXcsAjYV7vc">30,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--ExcercisePriceOneMember_zclxG24BTqv9">1.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231_zAJ5lpDUKtB5"><span style="-sec-ix-hidden: xdx2ixbrl0496">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zcLsGYubAzI3"><span style="-sec-ix-hidden: xdx2ixbrl0497">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zcHnC2D7iTi5">30,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--OptionExerciseMember_zSi9NrRm8YU8"><span style="-sec-ix-hidden: xdx2ixbrl0499">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220101__20221231_zzD3spWj1PD5"><span style="-sec-ix-hidden: xdx2ixbrl0500">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--OptionCancelledWeightedAverageMember_zl0DnbuBHS04"><span style="-sec-ix-hidden: xdx2ixbrl0501">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z9dNwsXSnCy4"><span style="-sec-ix-hidden: xdx2ixbrl0502">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_zENToWc58ue1"><span style="-sec-ix-hidden: xdx2ixbrl0503">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231_zms683xuYoa1"><span style="-sec-ix-hidden: xdx2ixbrl0504">—</span></span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--ExcercisePriceTwoMember_zPQE9hejR7v8">1.51</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table>
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
30000 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
30000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4539843 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4539843 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4539843 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4539843 shares

Files In Submission

Name View Source Status
skvi-20221231_cal.xml Edgar Link unprocessable
0001663577-23-000137-index-headers.html Edgar Link pending
0001663577-23-000137-index.html Edgar Link pending
0001663577-23-000137.txt Edgar Link pending
0001663577-23-000137-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_004.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skvi-20221231.xsd Edgar Link pending
skvi10k123122.htm Edgar Link pending
skvi-20221231_def.xml Edgar Link unprocessable
skvi-20221231_lab.xml Edgar Link unprocessable
skvi-20221231_pre.xml Edgar Link unprocessable
skvi10k123122_htm.xml Edgar Link completed